来宝网 2013/3/22点击1910次
科罗拉多州莱克伍德--(美国商业资讯)--Terumo BCT已经收购了Medservice,后者是一家为波兰血库和医院提供医疗产品与服务的领先分销商。
自2006年起,Medservice一直是Terumo BCT的分销商,为波兰血库提供服务。此项收购让Terumo BCT能够直接与波兰血库建立关系,推动可改善血液安全性与质量的关键输血技术在波兰的深入普及。
主要事实:
主要引言:
Terumo BCT高级副总裁兼欧洲、中东及非洲业务总经理Vincent Gaspar
“Medservice收购案彰显了我们的全球承诺,即通过技术来提高血液安全性,改善血液成分质量,进一步增强我们的全球产品。我们计划在Medservice良好的客户服务、品质和协作信誉的基础之上再接再厉,为客户提供范围更广的产品和服务组合。”
Terumo BCT高级副总裁兼欧洲、中东及非洲业务总经理Vincent Gaspar
“从战略层面来看,Medservice与我们不谋而合。它是一家经营得当的企业,拥有良好的客户服务、品质和协作信誉。通过这项收购,我们将巩固在波兰的强劲业务以及我们的血液安全与自动化计划所取得的成功。我们期待通过更多的实地资源为客户提供支持,让他们能够直接使用我们涵盖甚广的产品和服务。”
关于Medservice:
Medservice是一家总部位于波兰的企业,为国内外客户提供高品质的医疗产品和服务。其宗旨就是通过供应安全且符合药品领域最新发现的优质产品赢得并维持客户的信任与满意。
关于Terumo BCT:
Terumo BCT在血液成分、治疗性血浆分离置换法和细胞技术领域居全球领先地位,是唯一一家拥有血液分离置换采集、手动及自动全血处理和病原菌灭活独特组合的公司,此外,公司还在治疗性采集和细胞处理领域拥有领先技术。我们相信血液具有巨大潜能,能为患者提供比当今更多的治疗方法及更好的治疗效果。正是这一信念激励我们不断创新,并加强与客户间的紧密合作。
主要条款与完成时间:
该交易已确定采用购股形式,预计将于Terumo BCT的第四财季完成,但还取决于批准和惯例条件。交易完成后,Medservice将作为Terumo BCT Europe, N.V.旗下子公司开展运营。
特别提示:
本新闻稿中与未来业绩和事件有关的陈述为基于Terumo BCT和Medservice当前预期的前瞻性陈述。由于存在大量风险、不确定因素及其他因素,未来的实际业绩和事件可能会与前瞻性陈述中明示或暗示的产生实质性差异。风险、不确定因素和假设包括:可能未能如预期的那样实现预计的益处;交易可能未能及时完成(如若真的发生);Terumo BCT和Medservice未能顺利执行管理层的未来运营计划、战略和目标。
免责声明:本公告之原文版本乃官方授权版本。译文仅供方便了解之用,烦请参照原文,原文版本乃唯一具法律效力之版本。
联系方式:
Terumo BCT
D. Nikki Wheeler, +1-303-205-2828
全球企业通讯部
press@terumobct.com
Polish Medical Products and Services Distributor Provides Strategic Benefits
LAKEWOOD, Colo.—March 20, 2013 — Terumo BCT has acquired Medservice, a leading distributor of medical products and services to blood banks and hospitals in Poland.
Medservice has been a Terumo BCT distributor to blood banks in Poland since 2006. The acquisition provides Terumo BCT a direct relationship with Polish blood banks, to drive the further adoption of critical blood transfusion technologies that can improve the safety and quality of blood in Poland.
Key Facts:
Key Quotes:
Vincent Gaspar , Senior Vice President and General Manager EMEA, Terumo BCT
"The acquisition of Medservice underscores our global commitment to deliver technology that provides safer blood and improves the quality of blood components and further strengthens our global offerings. We plan to build on Medservice's strong reputation for customer service, quality and collaboration, and provide customers with a broader portfolio of products and services. "
Vincent Gaspar , Senior Vice President and General Manager EMEA, Terumo BCT
"Strategically Medservice is a great fit. It is a well-run company with a strong reputation for customer service, quality and collaboration. With this acquisition we will build on our strong presence in Poland and the success we have had with our blood safety and automation initiatives. We look forward to supporting our customers with additional field-based resources and in providing them with direct access to our wide range of products and services."
About Medservice:
Medservice is a Poland-based company providing high-quality medical products and services to domestic and foreign customers. Its mission is to gain and maintain customers' trust and satisfaction by supplying quality products that are safe and compliant with the latest findings in the field of medicine.
About Terumo BCT:
Terumo BCT , a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction coupled with leading technologies in therapeutic apheresis and cell processing. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.
Principal Terms and Closing:
The transaction has been structured as a share purchase and is expected to close in Terumo BCT's fourth fiscal quarter, subject to approval and customary conditions. After the closing, Medservice will be operated as a subsidiary of Terumo BCT Europe, N.V.
Special Note:
Statements that relate to future results and events are forward-looking statements based on Terumo BCT's and Medservice's current expectations. Actual results and events in future periods may differ materially from those expressed or implied by these forward-looking statements because of a number of risks, uncertainties and other factors. Risks, uncertainties and assumptions include the possibility that projected benefits may not materialize as expected; that the transaction may not be timely completed, if at all; that Terumo BCT and Medservice are unable to successfully implement the plans, strategies and objectives of management for future operations.
Contact:
D. Nikki Wheeler
Global Corporate Communications
Phone: +1.303.205.2828
press@terumobct.com